Canary Capital Files for Staked INJ ETF as Injective Eyes Earlier US Approval
Canary Capital has updated its SEC paperwork for a proposed Staked INJ ETF called INJC, which would hold INJ directly and stake about 90% of assets, with BitGo as custodian and a planned Cboe BZX listing. The filing joins at least three other pending INJ ETF applications, including ones from 21Shares and REX-Osprey. Injective CEO Eric Chen said a 2027 launch for US INJ-linked ETFs may be too conservative and suggested approval could come sooner.
Canary Capital's revised S-1 for INJC, submitted Sept. 24, 2026, describes a fund that would own INJ outright while staking roughly nine-tenths of assets. BitGo would safeguard tokens, and Cboe BZX is the intended listing venue. The application sits alongside pending INJ ETF proposals from 21Shares and REX-Osprey.
Injective is a Layer 1 network focused on finance and tokenization. CEO Eric Chen said in an Oct. 5, 2026 interview that waiting until 2027 for U.S. INJ ETFs may be too cautious. Separately, the Injective Foundation's Trench Treasury began in early Oct. 2026, with first funding for Sprout and RunUp.
Approval of staked INJ ETFs could broaden access for traditional brokerage investors, potentially letting them gain INJ exposure and staking-related yield without managing wallets. This may affect retail investors, advisors, and crypto-native holders by shifting some demand into regulated wrappers. It could also raise questions about liquidity, redemption handling, and investor understanding of staking risks. The outcome may influence how other crypto ETFs approach staking, though regulatory timing remains uncertain.